Increased N-acetylaspartate in model mouse of pelizaeus-merzbacher disease

Journal of Magnetic Resonance Imaging

Volumn 35, Issue 2, 2012, Pages 418-425

  Takanashi, Jun Ichi ^a,b   Saito, Shigeyoshi ^a   Aoki, Ichio ^a   Barkovich, A James ^c   Ito, Yukiko ^d   Inoue, Ken ^d  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b KAMEDA MEDICAL CENTER   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

hypomyelination; magnetic resonance spectroscopy; myelin synthesis deficient mouse; N acetylaspartylglutamate; N acetylaspartate; Pelizaeus Merzbacher disease

Indexed keywords

CREATINE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; GLUTAMINE; N ACETYLASPARTIC ACID; N ACETYLASPARTYLGLUTAMIC ACID; NEURON SPECIFIC NUCLEAR PROTEIN; NEUROTRANSMITTER;

ANIMAL EXPERIMENT; ARTICLE; ASTROCYTOSIS; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MOUSE; MYELINATION; NERVE CELL; NONHUMAN; OLIGODENDROGLIA; PELIZAEUS MERZBACHER DISEASE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTON NUCLEAR MAGNETIC RESONANCE; STEM CELL; THALAMUS;

EID: 84856259814     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22817     Document Type: Article

References (26)

1. Inoue K,. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics 2005; 6: 1-16. (Pubitemid 40394825)
2. Lee JA, Inoue K, Cheung SW, Shaw CA, Stankiewicz P, Lupski JR,. Role of genomic architecture in PLP1 duplication causing Pelizaeus-Merzbacher disease. Hum Mol Genet 2006; 15: 2250-2265. (Pubitemid 43985516)
3. Takanashi J, Sugita K, Tanabe Y, et al. MR-revealed myelination in the cerebral corticospinal tract as a marker for Pelizaeus-Merzbacher disease with proteolipid protein gene duplication. AJNR Am J Neuroradiol 1999; 20: 1822-1828.
4. Moffett JR, Namboodiri MAA,. Expression of N-acetylaspartate and N-acetylaspartylglutamate in nervous system. Adv Exp Med Biol 2006; 576: 7-26.
5. Moffett JR, Ross B, Arun P, Madhavarao CN, Namboodiri AM,. N-acetylaspartate in the CNS: from neurodiagnostics to neurobiology. Prog Neurobiol 2007; 81: 89-131. (Pubitemid 46282272)
6. Cecil KM, Kos RS,. Magnetic resonance spectroscopy and metabolic imaging in white matter diseases and pediatric disorders. Top Magn Reson Imaging 2006; 17: 275-293. (Pubitemid 46594177)
7. Van der Voorn JP, Pouwels PJ, Hart AA, et al. Childhood white matter disorders: quantitative MR imaging and spectroscopy. Radiology 2006; 241: 510-517. (Pubitemid 44632898)
8. Takanashi J, Inoue K, Tomita M, et al. Brain N-acetylaspartate is elevated in Pelizaeus-Merzbacher disease with PLP1 duplication. Neurology 2002; 58: 237-241. (Pubitemid 34084213)
9. Hanefeld FA, Brockmann K, Pouwels PJW, Wilken B, Frahm J, Dechent P,. Quantitative proton MRS of Pelizaeus-Merzbacher disease: evidence of dys- and hypomyelination. Neurology 2005; 65: 701-706. (Pubitemid 41285848)
10. Wolf NI, Willemsen MA, Engelke UF, et al. Severe hypomyelination associated with increased levels of N-acetylaspartylglutamate in CSF. Neurology 2004; 62: 1503-1508. (Pubitemid 38608186)
11. Komaki H, Sasaki M, Yamamoto T, Iai M, Takashima S,. Connatal Pelizaeus-Merzbacher disease associated with the jimpy (msd) mice mutation. Pediatir Neurol 1999; 20: 309-311. (Pubitemid 29203444)
12. 1H spectra with LCModel. NMR Biomed 2001; 14: 260-264. (Pubitemid 32611437)
13. Provencher SW,. LCModel & LCMgui user's manual. LCModel Version 6.2-3
14. Atwood T, Robbins ME, Zhu J-M,. Quantitative in vivo proton MR spectroscopic evaluation of the irradiated rat brain. J Magn Reson Imaging 2007; 26: 1590-1595. (Pubitemid 350291289)
15. Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP,. Chronic phencyclidine administration induced schizophrenia-like changes on N-acetylaspartate and N-acetylaspartylglutamate in rat brain. Schizophr Res 2005; 73: 147-152. (Pubitemid 40093875)
16. Burlina AP, Ferrari V, Burlina AB, et al. N-acetylaspartylglutamate (NAAG) in Pelizaeus-Merzbacher disease. Adv Exp Med Biol 2006; 576: 353-359.
17. Sartori S, Burlina AB, Salviati L, et al. Increased level of N-acetylaspartylglutamate (NAAG) in the CSF of a patient with Pelizaeus-Merzbacher-like disease due to mutation in the GJA12 gene. Eur J Paediatr Neurol 2008; 12: 348-350. (Pubitemid 351680711)
18. Mochel F, Engelke UF, Barritault J, et al. Elevated CSF N-acetylaspartylglutamate in patients with free sialic acid storage diseases. Neurology 2010; 74: 302-305.
19. Gow A, Southwood CM, Lazzarini RA,. Disrupted proteolipid protein trafficking results in oligodendrocyte apoptosis in an animal model of Pelizaeus-Merzbacher disease. J Cell Biol 1998; 140: 925-934. (Pubitemid 28141229)
20. Bhakoo KK, Craig TJ, Styles P,. Developmental and regional distribution of aspartoacylase in rat brain tissue. J Neurochem 2001; 79: 211-220. (Pubitemid 32946658)
21. Ghadge GD, Slusher BS, Bodner A, et al. Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc Natl Acad Sci U S A 2003; 100: 9554-9559. (Pubitemid 37033966)
22. Nishiyama A,. Glial progenitor cells in normal and pathological states. Keio J Med 1998; 47: 205-208.
23. Skoff RP,. Increased proliferation of oligodendrocytes in the hypomyelinating mouse mutant-jimpy. Brain Res 1982; 248: 19-31. (Pubitemid 12024455)
24. Urenjak J, Williams SR, Gadian DG, Noble M,. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types. J Neurosci 1993; 13: 981-989. (Pubitemid 23067586)
25. Bhakoo KK, Pearce D,. In vitro expression of N-acetyl aspartate by oligodendrocytes: implication for proton magnetic resonance spectroscopy signal in vivo. J Neurochem 2000; 74: 254-262. (Pubitemid 30012776)
26. Seitelberger F,. Neuropathology and genetics of Pelizaeus-Merzbacher disease. Brain Pathol 1995; 5: 267-273.